Moderna Recursion: Which Cutting-Edge Path Is Best in 2026
Two biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...
Why Price Weighting Biases Index Performance
Price weighting can skew an index toward higher-priced stocks. This explanation covers implications for interpretation and strategy.
26,532 articles
Raymond James Just Upgraded Fastly to Outperform on AI
Raymond James just upgraded Fastly to Outperform with a $23 price target after a sharp one-day drop, pointing to AI-d...
Texas’ Land Game Rewards: AI Reshapes Homebuilder Bets
AI-driven underwriting is redefining Texas land development. Firms with deep local knowledge win faster approvals and...
Daiwa Upgrades Qualcomm to Outperform on AI Pivot Bets
Daiwa upgrades Qualcomm to Outperform, increasing the target to $225 as analysts forecast a broader AI infrastructure...
Marvell’s AI Tailwinds Heating Time: Is Now the Buy?
Marvell Technology rides AI tailwinds into a breakout, delivering record quarterly momentum and a growing pipeline of...
Wingstop Down Year with Equity Woes: 3 Asset Plays
Wingstop has slumped 60% in the last year amid a negative equity balance sheet. Meanwhile, three asset-heavy stocks—r...
Intel Doubled AMD’s 2026 Gains, Should You Rebalance Now?
Intel has surged ahead in 2026, outpacing AMD by more than double in year-to-date gains. The rally prompts investors ...
Altria Just Posted Strongest Growth in Years So Far
Altria just posted strongest growth in years, signaling a potential turning point. But behind the headlines lie shift...
Boxx Mimics Treasury Yields, IRS Probes Tax Tactics
Alpha Architect’s BOXX aims to reproduce short-term Treasury returns without income distributions, but the IRS is exa...
SoFi Anthony Noto Bought the Dip: Should You Now?
SoFi CEO Anthony Noto quietly bought the dip in SOFI stock across four trades this spring. This article breaks down t...
IP Strategy Announces Share Repurchase Plan to 1M Shares
IP Strategy said its board approved a buyback of up to 1,000,000 common shares through Dec. 31, 2026, potentially tri...
Decades of History Tell Anything: Biotech Near $50 Set to Soar
A cash-generative biotech near $50 is drawing buyers amid a market shift toward defensible healthcare names. Here’s w...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status